// App-Quantinova.ai

3530 : Effect of pharmacogenetic-based selection of first-line chemotherapy on response rate and R0 surgery in metastatic CRC patients.

Researchers

Presenter

  • Albert Abad

Principal Investigators

  • Vicente Alonso

  • Pilar Garcia Alfonso

  • Jose Luis Manzano

  • Bartomeu Massuti

  • Manuel Benavides

  • Alfredo Carrato

  • Jordi Remon

  • Javier Gallego Plazas

  • Veronica Conde

  • Cristina Gravalos Castro

  • Manuel Valladares

  • Mariano Provencio

  • Ramon Salazar

  • Manuel Gallen

  • Fernando Rivera

  • Javier Sastre

  • Enrique Aranda

  • Eva Martinez-Balibrea

Medical Centers

  • Hospital Germans Trias i Pujol, Barcelona, Spain

  • Hospital Universitario Central de Asturias, Oviedo, Spain

  • H. Universitario Miguel Servet, Zaragoza, Spain

  • Gregorio Maranon Hospital, Madrid, Spain

  • Institut Catala d'Oncologia, Hospital Universitario German Trias i Pujol, Badalona, Spain

  • Albacete University Hospital, Albacete, Spain

  • H. Universitario Regional y Virgen de la Victoria, Malaga, Spain

  • Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain

  • Hospital de Mataro, Mataro, Spain

  • Servicio de Oncologia Medica, Hospital General Universitario de Elche, Elche, Spain

  • Medical Oncology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain

  • Hospital Doce de Octubre, Madrid, Spain

  • Complejo Hospitalario Universitario de A Coruna, A Coruna, Spain

  • Hospital Universitario Puerta de Hierro, Madrid, Spain

  • Institut Catala d'Oncologia, l'Hospitalet de Llobregat, Barcelona, Spain

  • University Hospital del Mar-IMIM, Barcelona, Spain

  • Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

  • Hospital Clinico San Carlos Madrid, Spain. Center affiliated to the Red Tematica de Investigacion Cooperativa (RD06/0020/0021). Instituto Carlos III, Spanish Ministry of Science and Innovation, Madrid, Spain

  • Reina Sofia Hospital, University of Cordoba, Maimonides Institute of Biomedical Research (IMIBIC). Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Cordoba, Spain

  • Institut Catala Oncologia - Institut Investigacio Germans Trias i Pujol, Badalona, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Bevacizumab

  • Capecitabine and oxaliplatin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT01071655

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved